Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform

Insu Therapeutics received a USPTO Notice of Allowance for U.S. patent application 18/513,373, covering buccal peptide delivery intended for its investigational insulin and semaglutide formulations. Formal issuance remains subject to fees and remaining formalities, and the allowance does not establish safety, efficacy, or regulatory approval. Hydreight previously invested C$300,000 and holds disclosed exclusive U.S. distribution rights for qualifying products, contingent on successful development and approvals.

Analysis

For Hydreight Technologies (NURS), the update adds option value, not near-term earnings visibility. A stronger IP position may improve Insu’s ability to attract development partners and preserve future distribution economics, but NURS’s disclosed U.S. rights remain contingent on product-specific development and regulatory approval. The key commercial uncertainty is whether the final patent claims meaningfully constrain competing delivery methods; an allowance is not proof of broad, enforceable protection. Nor does distribution infrastructure establish manufacturing readiness, prescribing uptake, or attractive economics for NURS.

The second-order competitive test is convenience versus delivery performance: patients and prescribers will not switch from established injectable or oral peptide options unless bioavailability, dosing reliability, safety, and usability are competitive. Existing peptide manufacturers could also pursue alternative non-injectable formats, limiting the value of a potentially narrow platform patent. The large GLP-1 market forecast is not a proxy for Insu’s addressable sales or NURS revenue.

Near term, any share-price response is likely sentiment-driven. Over 1–3 months, verify issued claims, Insu’s financing runway, development plans, and whether a partner or funded study emerges. Over 6–18 months, reproducible human pharmacokinetic and safety data—not patent milestones—would materially change the probability of commercialization. No valuation or current market reaction is supplied, so there is insufficient basis to call NURS mispriced. The contrarian point: investors may overvalue the distribution tie-up, while the more consequential upside would come from credible human data and partner validation.

Key Decisions for Investors

• Do not treat the allowance as a standalone NURS earnings catalyst; avoid chasing a move based only on the IP headline. The evidence supports monitoring, not a directional position without valuation and price-response context.
• Keep NURS on an event-driven watchlist. Before assigning material value to the Insu relationship, verify the issued patent claims and remaining term, the distribution agreement’s economics and exclusivity conditions, and Insu’s cash runway and development funding.
• A thesis upgrade requires human pharmacokinetic and safety results showing reliable peptide absorption, followed by a credible development partner or funded clinical plan. Laboratory, cell-culture, and animal proof of concept are not substitutes.
• Falsify the near-term optimism if final claims are materially narrower than expected, development is delayed for lack of funding, or early human data fail to show reproducible exposure or acceptable tolerability. Reassess if NURS guidance or disclosures demonstrate a funded, executable commercialization pathway.